Premium
Regeneron Pharmaceuticals Inc (REGN)
NASDAQ
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-01 | Mr. Arthur Frederick RyanIndependent Director | -100,00 | 70,52k | Vente | 701,76 - 714,13 | 15,80k | -0,63% |
| 2026-04-01 | Mr. Arthur Frederick RyanIndependent Director | -100,00 | 77,73k | Automatic Disposition | 771,32 - 779,71 | 15,90k | -0,63% |
| 2026-03-02 | Mr. Arthur Frederick RyanIndependent Director | -100,00 | 78,55k | Automatic Disposition | 777,46 - 789,28 | 16,00k | -0,62% |
| 2026-02-19 | Dr. Huda Y. ZoghbiIndependent Director | -1,64k | 662,79k | Derivative Exercise and Sale | 376,69 - 790,00 | 0,00 | - |
| 2026-02-09 | Mr. Jason PitofskySenior VP & Controller | -1 000,00 | 284,97k | Derivative Exercise and Sale | 492,00 - 778,35 | 4,48k | - |
| 2026-02-09 | Mr. Jason PitofskySenior VP & Controller | -1,04k | 808,08k | Automatic Disposition | 778,35 - 785,72 | 4,48k | -18,77% |
| 2026-02-09 | Mr. Arthur Frederick RyanIndependent Director | -100,00 | 77,85k | Automatic Disposition | 775,63 - 787,82 | 16,10k | -0,62% |
| 2026-01-07 | Dr. Bonnie L. BasslerIndependent Director | -1,50k | 638,82k | Derivative Exercise and Sale | 374,12 - 800,00 | 0,00 | - |
| 2025-12-31 | Dr. George D. YancopoulosCo-Founder, President, Chief Scientific Officer & Co-Chairman | -28,57k | 22,06M | Derivative Exercise and Sale | 772,09 | 1,13M | - |
| 2025-12-31 | Dr. Leonard S. SchleiferCo-Founder, President, CEO & Co-Chairman | -28,57k | 22,06M | Derivative Exercise and Sale | 772,09 | 687,98k | - |
| 2025-12-30 | Mr. George L. SingIndependent Director | 3,02k | 1,57M | Derivative Exercise and Retained Stock | 520,01 | 33,00k | 10,09% |
| 2025-12-30 | Mr. George L. SingIndependent Director | -6,19k | 1,57M | Derivative Exercise and Sale | 520,01 - 774,03 | 33,00k | - |
| 2025-12-09 | Mr. Daniel P. Van PlewExec. VP and GM of Industrial Operations & Product Supply | -2,55k | 1,79M | Sale to Issuer | 701,51 | 35,18k | -6,76% |
| 2025-12-09 | Dr. Andrew J. MurphyExec. VP of Research & Co-Chief Scientific Officer | -4,23k | 2,97M | Sale to Issuer | 701,51 | 52,21k | -7,49% |
| 2025-12-09 | Ms. Marion E. McCourtExec. VP of Commercial | -1,02k | 716,24k | Sale to Issuer | 701,51 | 14,55k | -6,56% |
| 2025-12-09 | Dr. George D. YancopoulosCo-Founder, President, Chief Scientific Officer & Co-Chairman | 14,94k | 8,30M | Derivative Exercise and Retained Stock | 555,67 | 1,13M | 1,34% |
| 2025-12-09 | Dr. George D. YancopoulosCo-Founder, President, Chief Scientific Officer & Co-Chairman | -131,87k | 19,23M | Derivative Exercise and Sale | 555,67 - 701,51 | 1,13M | - |
| 2025-12-09 | Dr. Leonard S. SchleiferCo-Founder, President, CEO & Co-Chairman | 17,58k | 9,77M | Derivative Exercise and Retained Stock | 555,67 | 687,98k | 2,62% |
| 2025-12-09 | Dr. Leonard S. SchleiferCo-Founder, President, CEO & Co-Chairman | -155,15k | 22,63M | Derivative Exercise and Sale | 555,67 - 701,51 | 687,98k | - |
| 2025-12-08 | Mr. Jason PitofskySenior VP & Controller | -989,00 | 705,10k | Sale to Issuer | 712,94 | 5,52k | -15,20% |
| 2025-12-08 | Mr. Daniel P. Van PlewExec. VP and GM of Industrial Operations & Product Supply | -1,91k | 1,36M | Sale to Issuer | 712,94 | 37,73k | -4,81% |
| 2025-12-08 | Dr. Andrew J. MurphyExec. VP of Research & Co-Chief Scientific Officer | -1,70k | 1,21M | Sale to Issuer | 712,94 | 56,44k | -2,92% |
| 2025-12-08 | Ms. Marion E. McCourtExec. VP of Commercial | -1,34k | 952,49k | Sale to Issuer | 712,94 | 15,57k | -7,90% |
| 2025-12-08 | Mr. Joseph J. LaRosaExec. VP, General Counsel & Secretary | -1,40k | 995,26k | Sale to Issuer | 712,94 | 42,32k | -3,19% |
| 2025-12-08 | Mr. Christopher R. FenimoreExec. VP of Finance & CFO | -992,00 | 707,24k | Sale to Issuer | 712,94 | 21,80k | -4,35% |
| 2025-11-20 | Mr. Joseph J. LaRosaExec. VP, General Counsel & Secretary | 1,76k | 980,20k | Derivative Exercise and Retained Stock | 555,67 | 41,23k | 4,47% |
| 2025-11-20 | Mr. Joseph J. LaRosaExec. VP, General Counsel & Secretary | -12,69k | 2,30M | Derivative Exercise and Sale | 555,67 - 736,77 | 41,23k | - |
| 2025-11-20 | Dr. Bonnie L. BasslerIndependent Director | -760,00 | 287,74k | Derivative Exercise and Sale | 371,40 - 750,00 | 0,00 | - |
| 2025-11-07 | Mr. Jason PitofskySenior VP & Controller | -431,00 | 280,77k | Vente | 651,43 | 4,44k | -8,84% |
| 2025-10-30 | Ms. Christine Ann PoonLead Independent Director | 2,71k | 1,41M | Derivative Exercise and Retained Stock | 520,01 | 3,52k | 337,31% |
| 2025-10-29 | Ms. Christine Ann PoonLead Independent Director | -6,50k | 872,68k | Derivative Exercise and Sale | 520,01 - 657,29 | 3,52k | - |
| 2025-10-29 | Dr. Andrew J. MurphyExec. VP of Research & Co-Chief Scientific Officer | 972,00 | 540,11k | Derivative Exercise and Retained Stock | 555,67 | 54,42k | 1,82% |
| 2025-10-29 | Dr. Andrew J. MurphyExec. VP of Research & Co-Chief Scientific Officer | -34,03k | 2,17M | Derivative Exercise and Sale | 555,67 - 648,82 | 54,42k | - |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
